- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT01207492
재발성 또는 전이성 색소성 융모 결절성 활막염/건활막 거대 세포 종양/미만성 거대 세포 종양 환자의 닐로티닙
재발성 또는 전이성 색소 융모 결절성 활막염/건활막 거대 세포 종양/미만형 거대 세포 종양 환자에서 닐로티닙의 효능에 대한 다기관 단일 제제 제2상 연구
Nilotinib is a drug that is used to treat a form of a blood cancer called leukemia. Nilotinib works by blocking the action of a protein that might be important for the growth of pigmented villonodular synovitis (PVNS). In this research study the investigators are testing whether nilotinib can stop the growth of PVNS or improve the symptoms experienced from PVNS.
연구 개요
상세 설명
- In this research study, each cycle of study drug dosing will last 4 weeks (28 days). During each cycle, participants will take nilotinib by mouth twice daily. During the first cycle, participants will come to the clinic on Days 1 and 8. For Cycles 2-4 and every 3 cycles thereafter, they will come to the clinic on Day 1.
- The following tests and procedures will be performed at specific time points during study treatment: MRI or CT scans; physical examinations; vital signs; blood work; questionnaires and EKG.
- Participants may continue in this research study for as long as they do not have serious side effects or their disease does not get worse.
연구 유형
등록 (실제)
단계
- 2 단계
연락처 및 위치
연구 장소
-
-
California
-
Santa Monica, California, 미국, 90403
- Sarcoma Oncology Center
-
Stanford, California, 미국, 94305
- Stanford University Medical Center
-
-
Florida
-
Tampa, Florida, 미국, 33612
- H. Lee Moffitt Cancer Center
-
-
Massachusetts
-
Boston, Massachusetts, 미국, 02215
- Dana-Farber Cancer Institute
-
Boston, Massachusetts, 미국, 02114
- Massachusetts General Hospital
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, 미국, 19111
- Fox Chase Cancer Center
-
-
Texas
-
Houston, Texas, 미국, 77030
- UT MD Anderson Cancer Center
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Histologically confirmed diagnosis of recurrent PVNS ( or diffuse-type giant cell tumor or tenosynovial giant cell tumor) that is unresectable, metastatic, or for which the patient refuses surgical intervention
- Progressive disease in the last 12 months, as demonstrated by imaging or clinical appearance of new tumors, in the opinion of the treating investigator
- At least one site of measurable disease according to RECIST 1.1 on MRI (or CT scan for metastatic disease)
- Any number or type of prior systemic therapies, with the exception of known or suspected CSF1 receptor inhibitors as outlined in exclusion criteria below
- 18 years of age or older
- Life expectancy greater than 6 months
- ECOG Performance Status of 0, 1 or 2
- Normal organ and marrow function as defined in the protocol
- QTc less than or equal to 450 ms on 12-lead ECG
- Negative urine or serum pregnancy test within days of start of study drug administration for women of childbearing potential.
- Women of childbearing potential and men must agree to use adequate contraception prior to study entry, for the duration of study participation, and for 3 months following study drug discontinuation
Exclusion Criteria:
- Prior treatment with known or suspected CSF1 receptor inhibitor, including nilotinib, imatinib, sunitinib, or sorafenib, or other approved or investigational tyrosine kinase inhibitors used for treatment of diffuse-type giant cell tumor
- Concurrent treatment with other investigational agents
- Inability to tolerate or contraindication to MRI scanning for participants with localized disease
- Impaired cardiac function
- Current treatment with strong CYP3A4 inhibitors that cannot either be discontinued or switched to a different medication prior to starting study drug
- Current treatment with any medications that have the potential to prolong the QT interval and that cannot either be discontinued or switched to a different medication prior to starting study drug
- Impaired gastrointestinal (GI) function or GI disease that may significantly alter the absorption of study drug
- Acute or chronic pancreatic disease
- Acute or chronic liver disease
- Another primary malignant disease requiring systemic treatment or radiation
- History of significant congenital or acquired bleeding disorder unrelated to cancer
- Major surgery within 28 days prior to Day 1 of the study
- Treatment with other investigational agents within 28 days of day 1
- History of non-compliance to medical regimens or inability to grant consent
- Women who are pregnant or breastfeeding
- Other comorbidities that would interfere with study participation or safety in the opinion of the investigator
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 해당 없음
- 중재 모델: 단일 그룹 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: Nilotinib
Nilotinib 200 mg taken as 400 mg twice daily, continuously |
Taken orally twice daily |
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Percentage of Participants With Progression Free Survival
기간: 6 months
|
To estimate progression free survival at 6 months in participants with recurrent PVNS treated with nilotinib. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions. |
6 months
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Overall Tumor Response Rate (OR)
기간: 2 years
|
To determine overall tumor response rate [% complete response (CR) + % partial response (PR) by RECIST 1.1]. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by MRI: Complete Response (CR) is a disappearance of all target lesions. Partial Response (PR) is a >=30% decrease in the sum of the longest diameter of target lesions. Overall Response (OR) = CR + PR. |
2 years
|
|
Clinical Benefit Rate
기간: 6 months
|
To determine the clinical benefit rate [% CR + % PR + % stable disease by RECIST 1.1] at 6 months. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by MRI: Complete Response (CR) is a disappearance of all target lesions. Partial Response (PR) is a >=30% decrease in the sum of the longest diameter of target lesions. Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study. |
6 months
|
공동 작업자 및 조사자
수사관
- 수석 연구원: Andrew J. Wagner, MD, PhD, Dana-Farber Cancer Institute
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (실제)
연구 완료 (실제)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (추정된)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
키워드
추가 관련 MeSH 약관
기타 연구 ID 번호
- 10-179
- YUS23T (기타 식별자: Novartis)
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .